Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Ritter Pharmaceuticals ($RTTR) provided details about the Phase 3 program for lactose intolerance (LI) candidate RP-G28. The program incorporates guidance from the FDA during their End-of-Phase 2 meeting. The two studies to be conducted under this phase will both have the change in LI symptom scores from baseline to day 30 as their primary endpoints. The secondary endpoints will measure patients' continued meaningful treatment benefit.
Ritter stock gained over 13 percent in its previous trading session. It lost 77 percent of its value this year so far while its 12 months loss stands at 55 percent.

Windtree Therapeutics ($WINT) stock jumped up as the company announced its new financial restructuring program. The company is looking to secure the required capital to support its AEROSURF respiratory distress syndrome program and advance its pipeline. Windtree has secured a $3.9 million loan from Hong Kong-based Lee's Pharmaceutical Limited. The loan will be disbursed in three equal tranches over the next two months. The company received the initial installment earlier this week.
Windtree stock reacted positively to the news and gained over 15 percent in its previous trading session, trimming its Year to Date losses to 83 percent.


Johnson & Johnson ($JNJ) reported a favorable verdict from a federal jury regarding defective design of a blood thinner. This is the third straight win for the company in Xarelto case. Johnson & Johnson was sued by more than 20,000 users of the drug.

Retractable Technologies ($RVP) stock slumped as the Texas District Court judge determined that Retractable is eligible for no compensation in its antitrust lawsuit against Becton, Dickinson & Company. The judge also dismissed the case. Retractable says it is mulling its options, including a motion for a new trial or amend the judgement and appeal the decision.

Teva Pharmaceuticals Industries ($TEVA) announced the launch of its generic version of Eli Lilly's Axiron (testosterone) topical solution CIII, 30mg/1.5mL in the U.S. The solution is used to treat adult men with low or no testosterone.
Endologix announced positive preliminary results from LEOPARD, a 458-subject comparative study between its AFX and AFX2 endografts and other commercially available bifurcated aortic endografts. The company is now planning to halt further randomization in LEOPARD and will continue to follow current participants for five years.


MiMedx Group ($MDXG) announced inking a new agreement with the former stockholders of Stability, Inc. to divest Stability Biologics back to them. Stability Biologics develops and processes bioactive bone graft products and tissue allografts and was acquired by MiMedx in January 2016.
Biocept ($BIOC) announced its new collaboration with the University of Texas Southwestern Medical Center to conduct a study. The new collaboration will assess the clinical utility of its Target Selector platform for patients with ALK-positive non-small cell lung cancer (NSCLC) who are being treated with an ALK inhibitor.

Brokerage Action Company Rating Price Target
Maxim Group Reiterates Adamis Pharmaceuticals Corporation (ADMP)
Buy $13.00
Cantor Fitzgerald Reiterates AxoGen (AXGN)
Royal Bank Of Canada Reiterates Medtronic PLC (MDT)
Buy $90.00
Royal Bank Of Canada Reiterates NuVasive (NUVA)
Buy $85.00
Janney Montgomery Scott Upgrades Pacira Pharmaceuticals (PCRX)
Sell -> Neutral

Gainers (% price change)Last TradeChangeMkt CapTenet Healthcare CorpTHC14.45+1.80 (14.23%)1.46BCTI BioPharma CorpCTIC3.35+0.23 (7.37%)143.99MImmunomedics, Inc.IMMU8.42+0.44 (5.51%)936.97MPeregrine PharmaceuticalsPPHM3.23+0.15 (4.87%)145.57MTrinity Biotech plc (ADR)TRIB5.45+0.23 (4.41%)131.02MLosers (% price change)Accelerate DiagnosticsAXDX21.70-1.85 (-7.86%)1.20BAchillion PharmaceuticalsACHN4.67-0.21 (-4.30%)638.68MNatus Medical IncBABY32.50-1.25 (-3.70%)1.08BSangamo Therapeutics IncSGMO9.90-0.35 (-3.41%)827.75MKeryx BiopharmaceuticalsKERX6.52-0.21 (-3.12%)774.25MMost Actives (dollar volume)Johnson & JohnsonJNJ132.63-0.41 (-0.31%)355.98BCelgene CorporationCELG127.65+0.07 (0.05%)99.87BUnitedHealth Group IncUNH190.82-1.88 (-0.98%)184.50BMerck & Co., Inc.MRK61.49-0.35 (-0.57%)167.71BPfizer Inc.PFE32.67-0.28 (-0.85%)194.55B